S230: CD22 CAR T CELL THERAPY IS SAFE AND EFFECTIVE IN PATIENTS WITH LARGE B CELL LYMPHOMA WHO HAVE RELAPSED AFTER CD19 CAR T CELL THERAPY.

פריטים דומים

• Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report
  מאת: Crystal Mackall, et al.
  יצא לאור: (2020-10-01)
• CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles’ Heel?
  מאת: Leonardo M. R. Ferreira, et al.
  יצא לאור: (2021-11-01)
• CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
  מאת: Lihe Su, et al.
  יצא לאור: (2022-12-01)
• Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
  מאת: Wenjie Li, et al.
  יצא לאור: (2023-03-01)
• Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy
  מאת: Nirali N. Shah, et al.
  יצא לאור: (2019-08-01)